EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer

Ying Jiang, Zhiwen Qian, Cenzhu Wang, Danping Wu, Lu Liu, Xin Ning, Yilan You, Jie Mei, Xiaoqian Zhao, Yan Zhang

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Ying Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, B7 Antigens, Immunotherapy, Fatty Acids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: General Program of Wuxi Medical Center of Nanjing Medical University, Doctoral Talent Fund of the Affiliated Wuxi People’s Hospital of Nanjing Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple-negative breast cancer (TNBC) is the most malignant breast cancer, highlighting the need for effective immunotherapeutic targets. The immune checkpoint molecule B7-H3 has recently gained attention as a promising therapeutic target due to its pivotal role in promoting tumorigenesis and cancer progression. However, the therapeutic impact of B7-H3 inhibitors (B7-H3i) remains unclear.

Methods

Transcriptomic and metabolomic analyses were conducted to explore the underlying mechanisms of B7-H3 inhibition in TNBC. The therapeutic efficacy of the combined treatment strategy was substantiated through comprehensive phenotypic assays conducted in vitro and validated in vivo using animal models.

Results

B7-H3 blockade induces a “primed for death” stress state in cancer cells, leading to distinct alterations in metabolic pathways. Specifically, B7-H3 knockdown activated the AKT signaling pathway and upregulated sterol regulatory element-binding protein 1 (SREBP1), which in turn elevated FASN expression. The simultaneous inhibition of both B7-H3 and FASN more effectively attenuated the malignant progression of TNBC.

Conclusions

Our findings propose an “immune attack-metabolic compensation” dynamic model and suggest the feasibility of a dual-targeting strategy that concurrently inhibits both B7-H3 and FASN to enhance therapeutic efficacy in TNBC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsB7 AntigensImmunotherapyFatty AcidsImmune Checkpoint InhibitorsHumansFemaleAnimalsMiceCell Line, Tumor

Stichwörter der Autor:innen

Breast CancerImmune Checkpoint InhibitorImmunotherapy

Substanzen

B7 AntigensCD276 protein, humanFatty AcidsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
  • Department of Oncology, Wuxi Maternal and Child Health Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, China.
  • The First Clinical Medicine College, Nanjing Medical University, Nanjing, Jiangsu, China meijie1996@njmu.edu.cn snoppyy1980@163.com fuyou2007@126.com.
  • Department of Breast Surgery, Women's Hospital of Jiangnan University, Wuxi, China meijie1996@njmu.edu.cn snoppyy1980@163.com fuyou2007@126.com.
  • Department of Oncology, Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China meijie1996@njmu.edu.cn snoppyy1980@163.com fuyou2007@126.com.

Förderung

  • General Program of Wuxi Medical Center of Nanjing Medical University
  • Doctoral Talent Fund of the Affiliated Wuxi People’s Hospital of Nanjing Medical University
  • National Natural Science Foundation of China
  • Wuxi Double-Hundred Talent Fund Project

Zitieren

APA

Jiang, Y., Qian, Z., Wang, C., Wu, D., Liu, L., Ning, X., You, Y., Mei, J., Zhao, X., & Zhang, Y. (2025). Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010924

Vancouver

Jiang Y, Qian Z, Wang C, Wu D, Liu L, Ning X, et al. Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010924

BibTeX
@article{Jiang2025,
  author = {Jiang, Ying and Qian, Zhiwen and Wang, Cenzhu and Wu, Danping and Liu, Lu and Ning, Xin and You, Yilan and Mei, Jie and Zhao, Xiaoqian and Zhang, Yan},
  title = {Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010924}
}
Kostenlos starten →